Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

Data demonstrating the superior performance over existing assays highlighted at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD™ 2024) international conference in Lisbon, Portugal. FREMONT, Calif., March 5, 2024 /PRNewswire/ — Alamar Biosciences, a company powering precision…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks